RA Session II retweeted
We’re pleased to share Health Canada has authorized our protocol amendment that expands eligibility to include patients aged 12 and older with #Rettsyndrome in the REVEAL Phase 1/2 adult trial. Learn more: ir.tayshagtx.com/news-releas…
RA Session II retweeted
We are excited to announce the first patient has been dosed in the REVEAL Phase 1/2 trial evaluating our investigational AAV9 #genetherapy for #Rettsyndrome. Learn more: bit.ly/3MPlk8T
RA Session II retweeted
We are excited to announce new preclinical data for our TSHA-102 #genetherapy program in evaluation for Rett Syndrome will be presented at the #ASGCT23 Annual Meeting on May 19. Learn more: https://xitter.gq/t.co/CVN4aLKFRT
Happy Thanksgiving to you and yours! This year has been filled with many significant milestones, with more in store for 2023, and I’m thankful for the @tayshagtx team’s continued hard work and dedication towards our goal of eradicating rare disease.
2
Excited to hear about learnings from Dirk’s participation in @TESSResearch's International Research Roundtable. This collaborative event will give researchers an opportunity to exchange ideas and make strides towards a brighter future for those impacted by SLC13A5.
🗣 Attention! Dirk Schmitt from @TayshaGTx will be speaking at TESS Research Foundation's 🌏 International Research Roundtable! 🔬Join us in Vienna, Austria 🇦🇹 on September 7-8. 💜 Learn more and register today: https://xitter.gq/t.co/eISiz24jGW #TESSRoundtable
In celebration of #WomensEqualityDay, I want to take a moment to recognize all the women that have helped make Taysha what it is today. You are living proof that women can be anything they want to be, which is not easy in a historically male-dominated industry.
1
2
School is back in session, and with quarantine guidelines recently lifted by the @CDCgov, immunization for our children is more important now than ever. As a parent myself, I encourage you all to explore all of the options available to you.
1
Last week, we reported Q2 earnings and I’m proud of Team @tayshagtx’s progress. We’re on track to report preliminary clinical data for TSHA-102 in Rett syndrome and plan to share a regulatory update on TSHA-120 in GAN, including from the FDA, by year-end.
This morning we announced our second quarter earnings. Click here to learn more: https://xitter.gq/t.co/GM3ZbUlIEE
3
1
In celebration of #PatientAppreciationDay, I’d like to thank our patients – thank you for trusting Team @tayshagtx with your stories and embracing us like family. It is our mission to bring new cures to life, and with your support, there’s no doubt that we’ll make it happen.
This week, we’re headed to two investor conferences hosted by BTIG & @Wedbush, where @tayshagtx’s CMO Suyash Prasad and myself will share the challenges and opportunities that arise in the pursuit of eradicating rare disease. Find out more here: https://xitter.gq/t.co/9lcL86DhcZ
Nicole represents just one of many families who, as #rareallies, advocate for loved ones living with rare disease. As we work towards developing treatments for SLC13A5 and the like, it’s important that we recognize those who are fighting the good fight alongside us every day.
#TBT Last month we participated in the TESS Foundation Research Conference and heard from Nicole, mom of Meredith who lives with SLC13A5 Deficiency. We walked away from her presentation on the family perspective energized about our work to develop a #genetherapy for #SLC13A5.
👏🏾 @USWNT’s continued success—from this win to their recent #equalpay agreement—make them a true inspiration to us all, both on and off the field.
Looks like we'll be seeing the @uswnt in Paris too 🤩
Yesterday, they qualified for the 2024 Summer Olympics after defeating Canada 1-0 to win the 2022 Concacaf W Championship 🎉
onherturf.nbcsports.com/2022…
Looking forward to tuning into our CMO Suyash Prasad’s panel discussion at the @WilliamBlair Biotech Focus Conference today. He’ll be discussing the process of delivering AAV gene therapies and what to expect post-development. You can learn more here: https://xitter.gq/t.co/fDNe0QzQDn
Today, our VP of Market Access, Brad Martin, will take part in a panel discussion re: the advancement of orphan drug development—a key initiative for Team Taysha. Hosted by the @OrphanConf, this discussion will drive our continued efforts as #rareallies.
Tomorrow Brad Martin, Vice President of Market Access, will participate in a panel at the @Terrapinn World Orphan Drug Congress. This event aims to help rare disease patients by advancing orphan drug development and improving access to life-saving therapies.
1
In a continued effort to eradicate rare disease, we stand with the @BDSRA and look forward to joining their Annual Family Conference for a week of advocacy and forward-looking discussion. We believe that a world without Batten disease is within reach.
Tomorrow marks the beginning of the @BDSRA Annual Family Conference. We remain committed in the fight against Batten disease and look forward to hearing patient stories throughout the weekend. Together we envision a world without #Battendisease.
In honor of National Make a Difference to Children Month, I’d like to take a moment to reiterate @tayshagtx’s commitment to our patients.
1
It’s all about doing right by our kids. We chose to focus primarily on eradicating rare diseases that impact children because they will ultimately shape the world we live in.
1














